Comparative Pharmacology
Head-to-head clinical analysis: CHOLOGRAFIN MEGLUMINE versus CONRAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLOGRAFIN MEGLUMINE versus CONRAY.
CHOLOGRAFIN MEGLUMINE vs CONRAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cholografin meglumine is an iodinated contrast agent that opacifies the biliary tract. It is actively taken up by hepatocytes and excreted into the bile, allowing radiographic visualization of the bile ducts and gallbladder.
Iothalamate meglumine is an ionic, high-osmolality radiopaque contrast agent that attenuates X-rays, allowing visualization of vascular structures and organs during radiographic procedures.
Intravenous: 20 mL (10.3 g) of a 52% solution (meglumine salt) administered by slow IV injection over 3-5 minutes; repeated once after 10-15 minutes if visualization is inadequate, not to exceed 40 mL total.
Intravenous: 20-60 mL for CT enhancement; intra-arterial: 5-80 mL per injection; concentration 282 mgI/mL (iothalamate meglumine). Dose based on procedure, body weight, and renal function.
None Documented
None Documented
Terminal elimination half-life is approximately 1-2 hours in patients with normal hepatic function, reflecting rapid biliary excretion; prolonged in hepatic impairment.
Terminal elimination half-life is approximately 2 hours in patients with normal renal function; prolonged in renal impairment.
Primarily hepatic excretion via bile into feces; renal excretion accounts for <1% of the dose in patients with normal hepatic function.
Primarily renal excretion via glomerular filtration; >90% of administered dose eliminated unchanged in urine within 24 hours. Less than 1% biliary or fecal.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent